美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kalaris Therapeutics Inc.

10.06

+0.930010.19%

盤後：9.86-0.2000-1.99%18:41 EST

成交量：10.91萬

成交額：107.83萬

市值：1.88億

市盈率：-2.91

高：10.23

開：9.18

低：9.18

收：9.13

52周最高：12.90

52周最低：2.14

股本：1,870.24萬

流通股本：430.93萬

量比：0.30

換手率：2.53%

股息：- -

股息率：- -

每股收益(TTM):-3.4594

每股收益(LYR):-10.4377

淨資產收益率：--

總資產收益率：-63.50%

市淨率：4.49

市盈率(LYR):-0.96

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Kalaris Therapeutics公佈TH103在未接受治療的血管新生性AMD中初步1a期數據積極

Kalaris Therapeutics：第一階段單次遞增劑量試驗預計年底前將披露初步臨牀數據

新聞稿：Kalaris擴展領導團隊，任命Matthew Gall為首席財務官

Kalaris Therapeutics正在招募TH103治療新生血管性年齡相關性黃斑變性的1B/2期多劑量遞增研究

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/KLRS"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":10.06,"timestamp":1766437200000,"preClose":9.13,"halted":0,"volume":109140,"hourTrading":{"tag":"盘后","latestPrice":9.86,"preClose":10.06,"latestTime":"18:41 EST","volume":964,"amount":9526.93,"timestamp":1766446911006},"delay":0,"floatShares":4309313,"shares":18702418,"eps":-3.459444,"marketStatus":"未開盤","change":0.93,"latestTime":"12-22 16:00:00 EST","open":9.18,"high":10.2263,"low":9.18,"amount":1078281.1537199998,"amplitude":0.1146,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.459444,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":9.13,"preHourTrading":{"tag":"盘前","latestPrice":9.18,"preClose":9.13,"latestTime":"09:29 EST","volume":235,"amount":2154.489165,"timestamp":1766413798415},"postHourTrading":{"tag":"盘后","latestPrice":9.86,"preClose":10.06,"latestTime":"18:41 EST","volume":964,"amount":9526.93,"timestamp":1766446911006},"volumeRatio":0.302377},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":4309313,"roa":"-63.50%","roe":"--","lyrEps":-10.437743,"volumeRatio":0.302377,"shares":18702418,"dividePrice":0,"high":10.2263,"amplitude":0.1146,"preClose":9.13,"low":9.18,"week52Low":2.14,"pbRate":"4.49","week52High":12.9,"institutionHeld":0,"latestPrice":10.06,"eps":-3.459444,"divideRate":0,"volume":109140,"delay":0,"ttmEps":-3.459444,"open":9.18,"prevYearClose":9.66,"prevWeekClose":9.13,"prevMonthClose":6.24,"prevQuarterClose":5.78,"fiveDayClose":8.5,"twentyDayClose":7.01,"sixtyDayClose":5.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61},{"market":"US","date":"2025-05-14","symbol":"KLRS","fiscalQuarterEnding":"2025/03","expectedEps":-0.78,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"pre","actualEps":-2.52},{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.2,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1762405200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2025-12-19","current":-2.907982,"percent":0,"low":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"high":-0.558935,"avg":-1.239018,"sd":0.659127,"marketCap":194879195},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195}],"updateTime":1766458307685},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142712562","title":"Kalaris Therapeutics公佈TH103在未接受治療的血管新生性AMD中初步1a期數據積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1142712562","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142712562?lang=zh_tw&edition=fundamental","pubTime":"2025-12-18 05:03","pubTimestamp":1766005389,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics公布TH103在未接受治疗的血管新生性AMD中初步1a期数据积极","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"1117531396","title":"Kalaris Therapeutics：第一階段單次遞增劑量試驗預計年底前將披露初步臨牀數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1117531396","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117531396?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 21:08","pubTimestamp":1762952910,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics：第一阶段单次递增剂量试验预计年底前将披露初步临床数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"gpt_icon":0},{"id":"1158357876","title":"新聞稿：Kalaris擴展領導團隊，任命Matthew Gall為首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1158357876","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158357876?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 20:34","pubTimestamp":1762173260,"startTime":"0","endTime":"0","summary":"首席财务官的任命增强了Kalaris的领导团队，以支持公司在治疗未接受治疗的nAMD患者的1b/2期研究中的持续增长。加利福尼亚州帕洛阿尔托，2025年11月3日—— Kalaris Therapeutics，一家致力于开发和商业化常见视网膜疾病治疗的临床阶段生物制药公司，今天宣布任命Matthew Gall，MBA为首席财务官。Matthew Gall表示：“在公司重要的发展时刻，我很高兴加入Kalaris Therapeutics的领导团队。我期待能够帮助Kalaris实现其改变视网膜疾病患者治疗格局的使命。”","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","BK4120","KLRS","BK4139"],"gpt_icon":0},{"id":"1104736870","title":"Kalaris Therapeutics正在招募TH103治療新生血管性年齡相關性黃斑變性的1B/2期多劑量遞增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1104736870","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104736870?lang=zh_tw&edition=fundamental","pubTime":"2025-09-15 20:04","pubTimestamp":1757937876,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics目前正在招募TH103用于治疗新生血管性年龄相关性黄斑变性的1B/2期多剂量递增研究患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KLRS\",params:#limit:6,delay:false,,,undefined,":[]}}